Regenesome Inc., a subsidiary of Space Seed Holdings Inc., has raised a total of 80 million yen in a Pre-Seed round through the issuance of J-KISS-type stock options, with Japan System Techniques Co., Ltd. (JAST) (Headquarters: Kita-ku, Osaka; President and CEO: Takeaki Hirabayashi) as the underwriter. This marks the first close for Regenesome, which plans to seek additional financing through loans from financial institutions.
About Regenesome
Regenesome is a research and development-focused startup dedicated to advancing anti-aging technology, with a primary focus on exosome research. Driven by the mission to address future challenges brought on by aging through biotechnological innovation, Regenesome upholds the following Mission, Vision, and Values:
Mission
To deliver anti-aging technologies applicable on Earth and essential for extending human life to the Moon by 2040.
Vision
To demonstrate viable anti-aging technology for healthspan by 2030.
Value
Building a foundation of scientific knowledge on exosomes.
Establishing networks for the practical application of space sciences.
Conducting R&D to tackle health-related challenges, including anti-aging solutions, both on Earth and in space.
What are Exosomes?
Exosomes are extracellular vesicles (40-150 nm) originating from endosomes, known for their role in transporting and processing materials absorbed outside the cell. Found across various cell types, exosomes contain RNA, DNA, lipids, and proteins essential for cellular communication, facilitating intercellular signaling that regulates various physiological and pathological processes.
Notably, exosomes play a role in modulating immune responses by adjusting interactions between immune cells, influencing inflammatory responses, and controlling immune disorders. Additionally, exosomes are released by cancer cells, carrying factors that contribute to cancer proliferation, angiogenesis, and immune suppression. Exosomes also hold potential in regenerative medicine by transporting growth factors and microRNAs that aid in tissue repair and regeneration.
Regenesome’s Business Scope
Regenesome conducts omics analysis on cultured cells and human clinical trials under different environmental conditions, meticulously analyzing exosomes to explore their production and functionality within organisms. Through these research efforts, Regenesome aims to uncover knowledge on anti-aging methods using exosomes, contributing to advancements in space medicine as well as enhancing medical technologies on Earth. Key business initiatives include:
-
Development of supplements, food products, and cosmetics utilizing exosomes.
-
Development of new products and services based on substances found in cells.
-
Intellectual property management.
-
Consulting services for management, sales, and research.
-
Planning, producing, and managing various events.
-
Photography and video services, including production and sales.
-
All related services and activities.
Purpose of Financing
As society’s demand for longevity intensifies, the potential of nanoparticles, including exosomes, is expanding in medical and research fields. In the realm of space development, the need for anti-aging technology to enable prolonged space missions is increasingly apparent. Recognizing these demands, Space Seed Holdings, participating in the SPACE FOODSPHERE team and the Healthspan Program of the U.S.-based XPRIZE Foundation, established Regenesome in July 2024 to realize anti-aging measures through nanotechnology.
Objectives of Fundraising
By leveraging the relationship assets of Space Seed Holdings, Regenesome aims to conduct a Proof of Concept (POC) within 18 months. Following this, preparations for the next development phase will commence, ultimately striving to reduce societal burdens related to aging and expand human living environments beyond Earth.
Comments on the Financing Round
Takeaki Hirabayashi, President and CEO of JAST
“The business potential for exosome-related technologies in regenerative medicine, longevity, and healthspan is significant. We are confident that Regenesome’s cutting-edge technology has the potential to lead this market. Our Pre-Seed investment aligns with this belief, and we also envision future alliances with our brand business.”
JAST Future Co-Creation Lab: Director Ichihara and Co-Creation Lead Choi
“The Future Co-Creation Lab is an organization dedicated to solving social challenges through IT. Through this investment, we will support Regenesome’s endeavors in regenerative medicine, longevity, and healthspan extension, advancing societal solutions for the future. Our collaboration with leaders like Mr. Suzuki and Mr. Sakuma, who bring extensive expertise in research and management, will drive these joint efforts forward.”
Kengo Suzuki, CEO of Regenesome (Co-founder and Executive Fellow of Euglena)
“With growing needs to reduce social burdens associated with aging, there is substantial demand for advancements in anti-aging technology. By collaborating with JAST, a leader in IT infrastructure, we anticipate accelerated digital transformation (DX) in research and development, which will enable timely and reliable implementation.”
Zentaro Sakuma, President of Regenesome
“Exosome research holds limitless possibilities, not only for improving quality of life but also for supporting humanity’s future in space. We look forward to developing partnerships with numerous research institutions, with JAST’s historical expertise and analytical technologies as an essential foundation in our research and business development.”
Company Overview: Regenesome Inc.
CEO: Kengo Suzuki; President: Zentaro Sakuma
Headquarters: Minato-ku, Tokyo
Founded: July 12, 2024
Business: Exosome R&D
Website: https://regenesome.com
Company Overview: Japan System Techniques Co., Ltd. (JAST)
CEO: Takeaki Hirabayashi
Headquarters: Kita-ku, Osaka
Established: March 26, 1973
Listed: Tokyo Stock Exchange Prime Market (Code: 4323)
Business: DX & SI, Package Solutions, Medical Big Data, Global Business
Website: https://www.jast.jp
JAST’s Future Co-Creation Lab
JAST’s Future Co-Creation Lab collaborates with academia, government, and startups to foster new business ventures and address societal challenges. The Lab will continue to explore these efforts, enhancing JAST’s corporate value and expanding solutions for clients.
About Space Seed Holdings Co., Ltd.
Space Seed Holdings Co., Ltd., driven by the mission “Turning Sci-Fi into Non-Fiction,” invests in emerging technologies, nurtures startups, and engages in joint research with universities to tackle societal challenges. Ultimately, the company aims to advance the technology necessary for space habitation in collaboration with stakeholders. Utilizing its academic network and knowledge, Space Seed Holdings will continue contributing new, science-based services and products that address societal issues.
Inquiries:
Japan System Techniques Co., Ltd.
Future Co-Creation Lab: Ichihara, Choi
TEL: 03-6718-2785
Mail: JAST-Lab@jast.co.jp
URL：https://www.jastlab.jast.jp/
HR & General Affairs Department: Yamashita, Ishida
TEL: 06-4560-1000
Mail: press@jast.co.jp
Regenesome Inc.
representatives: Suzuki, Sakuma
Mail：info@regenesome.com
